Once a drug is approved, health care providers generally may prescribe it for an unapproved use when they judge it medically appropriate, but FDA has not determined that the drug is safe and effective for that use.1 A familiar GLP-1 example is Ozempic or Mounjaro prescribed for weight loss in someone without diabetes.
What approval covers
Before approval, the company must submit clinical data and show that the drug is safe and effective for its intended uses. FDA says "safe" does not mean free of side effects: it means the benefits for that use outweigh the potential risks. An approved use comes with labeling that lists the conditions the drug treats, how to use it for them, its risks, and what providers should discuss with patients. Some drugs also have Medication Guides, Patient Package Inserts and Instructions for Use written for patients.1 For an off-label use, FDA has made no such determination.
What each GLP-1 label covers
These are the approved uses as the first section of each label lists them in 2026:
- Wegovy injection, 3 uses: reducing the risk of major heart events in adults with heart disease and obesity or overweight. Also weight reduction and maintenance in adults and children 12 and older, and MASH, a fatty liver disease, with moderate to advanced fibrosis in adults.2
- Ozempic injection, 3 uses: blood sugar control in type 2 diabetes; reducing heart risk in type 2 diabetes with heart disease; and reducing kidney and heart risk in type 2 diabetes with chronic kidney disease.3
- Rybelsus and Ozempic tablets, 2 uses: blood sugar control in type 2 diabetes, and reducing the risk of major heart events in type 2 diabetes at high risk.4
- Zepbound, 2 uses: weight, and obstructive sleep apnea in adults with obesity.5
- Mounjaro, 1 use: blood sugar control in type 2 diabetes.6
- Saxenda, 1 use: weight reduction and maintenance in adults, and in children 12 and older who weigh more than 60 kg and have obesity.7
Read against this list, Ozempic, Rybelsus and Mounjaro for weight loss alone are off-label, while Wegovy, Zepbound and Saxenda are approved for it. Semaglutide and tirzepatide are each sold under more than one brand name with different labels: the weight-loss brands carry the weight indication, and the diabetes brands do not.
Doses and forms count too
FDA's definition goes beyond the condition. A drug given in a different form, such as a liquid instead of an approved capsule, or at a different dose from the label, is also an unapproved use.1 The labels set out the approved doses and the steps between them, and a schedule outside them falls in the same category.
Why providers prescribe off-label
FDA gives two common reasons. There may be no approved drug for the condition, or a person may have tried all the approved treatments without benefit. In cases like these, the patient and the provider may discuss using an approved drug for an unapproved use.1
Questions FDA suggests asking
- What is the drug approved for, and are there approved treatments for my condition?
- What studies support this use, and is it likely to work better than an approved option?
- What are the possible benefits and risks?
- Will my health insurance cover it for this use?
- Is there a clinical trial of this use I could join?
Adapted from FDA, understanding unapproved use of approved drugs.1
Sources
- U.S. Food and Drug Administration. Understanding unapproved use of approved drugs "off label". Content current as of February 5, 2018, read November 20, 2026. fda.gov
- WEGOVY (semaglutide) injection prescribing information. Novo Nordisk; DailyMed, version 19, published June 30, 2026; section 1. dailymed.nlm.nih.gov
- OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 1, 5.6 and 14.3. accessdata.fda.gov
- RYBELSUS and OZEMPIC (semaglutide) tablets prescribing information. Novo Nordisk; DailyMed, version 14, published August 19, 2026; section 1. dailymed.nlm.nih.gov
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; section 1. accessdata.fda.gov
- MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; sections 1, 2, 4, 5, 6.1, 8.3, 11, 12 and 14. accessdata.fda.gov
- SAXENDA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, version 22, published June 15, 2026; section 1. dailymed.nlm.nih.gov
Related analyses
Ozempic vs Wegovy: the same drug under two labels, compared by dose, results and price
Mounjaro vs Zepbound: the same drug under two labels, compared by use, results and price
Ozempic vs Zepbound: two drugs, two labels, and the trials that compared them
GLP-1 cost without insurance: every manufacturer self-pay price, dose by dose
Log which brand and use your prescription is for, so insurance questions have an answer.
Open Dose Insider